DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Information source: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Head and Neck Cancer

Intervention: Pralatrexate With Vitamin B12 and Folic Acid (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Memorial Sloan Kettering Cancer Center

Official(s) and/or principal investigator(s):
Alan Ho, MD, PhD, Principal Investigator, Affiliation: Memorial Sloan Kettering Cancer Center

Summary

The purpose of this study is to find out if the experimental drug pralatrexate with the vitamins folic acid and vitamin B12 might be an effective treatment for head and neck cancer. The reason we are doing this study is because another drug called methotrexate has been used for a long time to treat head and neck cancer patients. Pralatrexate was designed by scientists to be a new drug that works better than methotrexate. Laboratory studies have shown that pralatrexate works better than methotrexate at killing cancer cells. Pralatrexate has already been studied in patients with other types of cancers, such as lymphoma and lung cancer. The results from those studies were promising. Pralatrexate was recently approved by the Food and Drug Administration (FDA) as a new treatment for a cancer called peripheral T cell lymphoma.

Clinical Details

Official title: A Multi-Institution Phase II Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To determine the overall response rate (CR+PR)

Secondary outcome:

To determine the best overall response rate

To estimate median progression free survival (PFS).

To estimate median overall survival (OS).

To quantify the mRNA transcript levels of reduced folate carrier (RFC-1)

To evaluate the impact of pralatrexate on circulating endothelial cells (CECs) and circulating progenitor cells (CPCs)

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients must have histopathologically confirmed recurrent and/or metastatic squamous

cell carcinoma of the head and neck, including unknown primary squamous cell carcinomas of the neck. Confirmation of biopsy/diagnosis will be performed at MSKCC or at participating sites (NYU Cancer Institute/NYU Medical Center/ Bellevue Hospital Center).

- Patients must be at least 18 years of age.

- ECOG performance status must be ≥ 0 or 1.

- Disease must be measurable by RECIST version 1. 1 criteria.

- Patients must have been previously treated with systemic chemotherapy (i. e.,

chemotherapy and/or targeted therapies such as cetuximab for recurrent/metastatic HNSCC,.

- At least four weeks must have elapsed from previous radiation therapy. Patients must

have recovered from the acute toxic effects of treatment prior to study enrollment.

- Patients must have adequate organ function, as follows:

Adequate bone marrow reserve: absolute neutrophil count (ANC) > 1,000 cells/mm3, platelets > 100,000 cells/mm3, and hemoglobin > 9 g/dL Hepatic: AST and ALT ≤ 3 X upper limit of normal (ULN); AST and ALT ≤ 5 X ULN if liver metastasis present; Total bilirubin ≤ 1. 5 x ULN unless Gilbert's disease is present Renal: Serum creatinine ≤ 1. 5 mg/dL or creatinine clearance (by either 24 hour urine collection or Cockcroft-Gault equation) > or = to 55 ml/min

- Both women and men and members of all races and ethnic groups are eligible for this

trial.

- Women of childbearing potential must have a negative serum pregnancy test within 14

days of treatment. Both men and women must agree to use a reliable method of birth control until 30 days following the last dose of study drug. Exclusion Criteria:

- History of any brain metastases unless resected with no evidence for > 12 weeks and

not on steroids

- Women who are lactating

- Other active malignancy, other than indolent malignancies which the investigator

determines are unlikely to interfere with treatment and safety analysis

- Patients who have undergone an allogeneic stem cell transplant

Locations and Contacts

Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States

Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York 11725, United States

Memorial Sloan-Kettering Cancer Center, New York, New York 10065, United States

Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre, New York, United States

Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow, New York, United States

Additional Information

Memorial Sloan-Kettering Cancer Center

Starting date: August 2010
Last updated: April 9, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017